Crosstalk between CML cells with HUVECS and BMSCs through CML derived exosomes

Area of Science:

• Hematology
• Oncology
• Molecular Biology

Background:

• Chronic Myeloid Leukemia (CML) is a myeloproliferative neoplasm driven by the BCR-ABL fusion gene.
• Tyrosine Kinase Inhibitors (TKIs) are standard CML treatment, but resistance and progression remain challenges.
• The tumor microenvironment, including exosomes, is increasingly recognized for its role in cancer progression.

Purpose of the Study:

• To review the biological and clinical significance of exosomes derived from CML cells.
• To summarize recent research on the role of CML exosomes in therapy resistance and disease progression.

Main Methods:

• Literature review of studies investigating CML exosomes.
• Analysis of mechanisms by which CML exosomes influence cancer cell behavior and drug resistance.

Main Results:

• CML exosomes facilitate intercellular communication within the bone marrow microenvironment.
• Exosomes contribute to BCR-ABL dependent and independent mechanisms of TKI resistance.
• Exosomes play a role in the progression of CML from chronic to advanced phases.

Conclusions:

• CML-derived exosomes are critical mediators of therapeutic resistance and disease progression.
• Targeting exosome-mediated signaling represents a potential strategy for overcoming CML treatment challenges.
• Further research into CML exosomes is warranted to develop novel therapeutic approaches.